VANCOUVER, BC / ACCESSWIRE / May 29, 2015 / Naturally Splendid Enterprises Ltd. (“Naturally Splendid”) (NSP – TSX Venture) (NSPDF – OTCQB) (50N.F – Frankfurt) is pleased to announce that it has closed the initial tranche of its previously announced private placement financing by issuing a total of 3,257,300 units (the “Units”) for gross proceeds of $1,628,650.

Each Unit is comprised of one common share of Naturally Splendid and one-half of one common share purchase warrant (“Warrant”), with each whole Warrant entitling the holder to purchase one additional common share at $0.75 per share for a period of two years from the date of the issue. Naturally Splendid will have the right to accelerate the expiry date of the Warrants if, at any time, the average closing price of Naturally Splendid’s common shares is equal to or greater than $1.00 for 10 consecutive trading days. In the event of acceleration, the expiry date will be accelerated to a date that is 30 days after Naturally Splendid issues a news release announcing that it has elected to exercise this acceleration right.

In connection with the initial tranche of the financing, Naturally Splendid paid finders a cash commission totaling $36,532 and issued a total of 73,064 finder’s warrants. Each finder’s warrant is on the same terms as the Warrants.

The securities issued under the financing will be subject to a hold period expiring on September 29, 2015 pursuant to applicable securities laws and the rules of the TSX Venture Exchange.

Proceeds of the financing will be used for product development and working capital and corporate purposes.

The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended, (the “U.S. Securities Act”) or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of Naturally Splendid’s securities in the United States.

About Naturally Splendid Enterprises Ltd.

Naturally Splendid has an exclusive licensing agreement to market and distribute, the full complement of patent pending, plant-based omega products created by Boreal Technologies. The products include HempOmega(TM) and H2Omega(TM), as well as the AlgaeOmega(TM) FlaxOmega(TM), CanolaOmega(TM), and ChiaOmega(TM) plant based omega products. These novel products utilize microencapsulation and are available in both a powder format and an aqueous solution for increased flexibility in ingredient applications and stand-alone products. Additionally, Naturally Splendid has licensed from FSL progressive cannabinoid extraction and formulation technologies including the world’s first water soluble cannabinoid patent.

Naturally Splendid’s 100% owned NATERA(TM) line of hemp-based superfood products are carried nationwide by Canada’s leading health food distributors and a network of retail stores across Canada including major retailers and specialty stores. Naturally Splendid’s recently rebranded “NATERA(TM)” line of products includes natural and flavored shelled hemp seeds as well as natural and flavored hemp protein powders.

About POS Bio-Sciences

POS Bio-Sciences offers expertise and service in bioprocessing applied research from bench-top to commercialization scale. POS’ focus is process development, analytical services, and custom processing as well as specializing in extraction, fractionation, modification and purification of bio based materials.

All POS Bio-Sciences processes are GMP-compliant and fully supported by quality assurance, commitment to regulatory compliance, and certification to international standards. POS’ also offers a suite of support services to assist clients and ensure that project outcomes meet their needs and expectations.

POS Bio-Sciences is a registered business name of POS Management Corp.

About Full Spectrum Labs Limited

Full Spectrum Laboratories, LTD. incorporated in Ireland, is a bioresearch and product development company with operating subsidiaries in Canada and the United States. The company has principally focused on the plant cannabis sativa and has developed numerous technologies and made several discoveries resulting in two granted patents and over 11 patent applications, in just under 5 years. FSL currently concentrates on formulation and extraction technologies; analytical cannabis testing in Canada; advance cannabis plant breeding specializing in CBD expression; and cannabinoid bio-synthesis

For more information e-mail info@naturallysplendid.com or call 604-673-9573

On Behalf of the Board of Directors

J. Craig Goodwin
CEO, Director

Contact Information

Naturally Splendid Enterprises Ltd.
(NSP – TSX Venture; NSPDF – OTCQB; 50N.F Frankfurt)
2435 Beta Avenue
Burnaby, BC, V5C 5N1
Phone: (604) 559-8051
Fax: (604) 570-0934
E-mail: info@naturallysplendid.com
Website: www.naturallysplendid.com

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid’s control including, but not limited to, Naturally Splendid’s ability to complete the balance private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: Naturally Splendid Enterprises Ltd.  

ReleaseID: 429367

MANCHESTER, NH / ACCESSWIRE / May 29, 2015 / Management of QED Connect, Inc. (PINKSHEETS: QEDN) today announced that Ms. Kate Bahnsen, CEO of Oro Verde Inc. (formally known as Green M&A Solutions), has joined the Board of Directors of QED and will serve as the President and CFO.

Ms. Bahnsen brings a strong knowledge of the Gold market and mining companies doing exploration in Colombia and Africa. She has familiarity in Colombian and US Tax law, Corporate Law, and International Trade Law and an extensive understanding of trade finance. Ms. Bahnsen is fluent in several languages with more than 15 years of experience in corporate infrastructure, management, taxes, finance, marketing, sales and sales goals, budget, cost accounting, and world accounting standards. She has performed financial business analysis, and audits of multi-million dollars projects in China, Maldives, India, Greece, Macedonia, Japan and the USA.

Ms. Bahnsen holds a Master in Business Administration MBA with concentration in Financial Analysis from DeVry University Keller Graduate School of Accounting and Finance. She has a Bachelor in Management with a concentration in Marketing, Hospitality, Green Energy and Global Businesses from the University of Phoenix and a Bachelor of Science in Law National Paralegal College. Ms. Bahnsen also has a Minor in Accounting from the University of Reno and University of San Jose and an Associate in Veterinary Medicine from the Universidad the La Salle.

Tom Makmann, Chairman & CEO of QED Connect, commented; “We are very fortunate to have Kate joining the Company bringing her extensive experience and especially with her background in the gold marketing and mining business. We are now confident that we will be capable of maximizing the output at the projects in Colombia locations and expand the operations with additional opportunities in Colombia and the US.”

Kate Bahnsen, CEO of Oro Verde Inc. stated, “I am very excited to part of this team and believe that the Company is now ready to realize its potential. I am looking forward to building a world class operation; taking the operation at La Palmichala, Yurani and Hidalgos mine sites to their next level. We are now well positioned to generate increased revenue and improved profits through the reduction in costs and improved efficiencies.”

The closing of the acquisition is expected to be completed in the next few weeks pending the finalization of the due diligence.

Green M&A Solution has changed its name to Oro Verde Inc. www.oroverdeinc.com.

About QED Connect, Inc.

QED Connect, Inc. is a holding company which makes acquisitions, investments, and enters into strategic business partnerships. The Company works with organizations that are looking for capital, management assistance, or help in reaching their target markets to realize their true potential. QED’s business model allows it to achieve its goals by expanding its overall revenue and profits potential through multiple market segments. www.qedconnect.com

Safe Harbor Statement

Certain statements in this press release that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “future,” “may,” “will,” “would,” “should,” “plan,” “projected,” “intend,” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of QED to be materially different from those expressed or implied by such forward-looking statements. QED’s future operating results are dependent upon many factors, including but not limited to the Company’s ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company’s control; and (iv) other risk factors.

For more information contact:

Tom Makmann
Tel: (603) 425-8933
Fax: (541) 764-6180
Email: info@qedconnect.com 

SOURCE: QED Connect, Inc.

ReleaseID: 429351

New Executives Possess Public Company Experience

LOS ANGELES, CA / ACCESSWIRE / May 29, 2015 / Diego Pellicer Worldwide, Inc. (PINKSHEETS: DPWW) “Diego,” a real estate and a consumer retail development company that is focused on developing Diego Pellicer as the world’s first “premium” marijuana brand, today announces the appointments of Ron Throgmartin, as Chief Executive Officer, and David Wells, as Chief Financial Officer. The prior executives were part of a consulting contract with FSCOO, a California-based consulting firm, whose contract expired without renewal.

FSCOO has a proven track record of success in the coordination of projects within the hospitality industry, modifying existing operations, and developing systems for clients, which work effectively, specific to the client’s needs.

Alan Valdes, Chairman of Diego Pellicer, stated, “Specifically, FSCOO was hired to develop compliance systems and procedures for our company, including Financial/Accounting, Securities Compliance, Human Resources and Management. Diego is all about compliance, professionalism and consistency, which happen when you have trained people and proper systems and procedures in place. FSCOO has done a great job in assisting us with this goal.”

The FSCOO team included senior level executives from highly successful companies such as California Pizza Kitchen, Wolfgang Puck, House of Blues, Hard Rock, and Playboy. FS COO provided Diego with their CEO, Philip Gay and their CFO, Nick Roberts. Both will be stepping down at the end of the FS COO contract.

Taking the CEO position will be Diego’s former CEO, Ron Throgmartin. Mr. Throgmartin assisted his family in building a retail business that spread across 23 states with several billion in revenue and is currently traded on the NYSE. He also has extensive experience in real estate, agriculture and marijuana business development, including retail, grow and edible manufacturing.

RON THROGMARTIN, Chief Executive Offi­cer

– Assisted in developing family retail and brand business, which is currently in 16 South Eastern States, and is doing $2.4BN in annual revenue. The company is publically traded on the NYSE. Entrepreneur who has developed several successful small businesses. Owned a development company and built out over 3.5MM square feet. Partner in developing largest privately held beef cattle heard in USA.
– Consulted on the development of grow and retail operations for Marijuana in Colorado. Successfully managed the complicated state licensing process for retail and grow operations.
– Education background: Ball State University, BS

Stepping into the CFO position will be David Wells. Mr. Wells is the Founder of Wells Compliance, an accounting firm specializing in public company compliance. He has been CFO of several public and pre-public companies and led multiple public offerings, private offerings and M&A transactions.

DAVID WELLS, Chief Financial Offi­cer

David R. Wells has served as CFO of several public and pre-public companies and led multiple public offerings, private placements, and M&A transactions: Sionix Corporation (OTCBB: SINX), Voyant International Corporation (OTCBB: VOYT), PowerHouse Technologies Group, Inc. (now Migo Software, Inc.). He has served in numerous other companies as a consultant, including BroadStream, Inc., Hollywood Stock Exchange (HSX.com), and Cord Blood America, Inc. David is the Founder and Chief Executive Officer of Wells Compliance Group, and the creator of F.A.C.T.S. – the innovative cloud-based platform for public companies to outsource preparation of SEC reports. He holds an MBA from Pepperdine University and has been involved in several charitable organizations – The Leukemia Foundation (Team in Training) and Associated Services for International Adoption (ASIA).

Ron Throgmartin, Chief Executive Officer of Diego Pellicer, stated, “It was a pleasure working with FSCOO and we appreciate the consulting and systems they contributed to Diego as we transitioned from a private to a public company.”

The Official end of the FSCOO contract is May 31st, 2015.

About Diego Pellicer Worldwide, Inc.

Diego Pellicer Worldwide, Inc. is a real estate and a consumer retail development company that is focused on developing Diego Pellicer as the world’s first “premium” marijuana brand by adhering to the highest quality and standards for its facilities along with both cannabis and non-cannabis products. The company’s initial focus is to acquire and develop legally compliant real estate locations for the purposes of leasing them to state licensed companies in the cannabis industry. Diego does not grow or sell marijuana or marijuana infused products in the early stages of this plan.

For more information, check out: http://diegopellicer.com.

Forward-Looking Statements

Forward-Looking Statements. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Form 8-K filed on March 19, 2015, including but not limited to the discussion under “Risk Factors” therein, which the Company has filed with the SEC and which may be viewed at http://www.sec.gov.

Contact Information

Hayden IR
Cameron Donahue
cameron@haydenir.com
651-653-1854

SOURCE: Diego Pellicer Worldwide, Inc.

ReleaseID: 429356

MONARCH BAY, CA / ACCESSWIRE / May 29, 2015 / Microelectronics Technology Company (PINKSHEETS: MELY) announces pending planned expansion in its Bitcoin server mining operation.

The Company is moving forward in the next phase of its planned expansion of its Bitcoin mining operation, as it has entered into a letter of intent to acquire electricity at the lowest price available to a bitcoin mining operation in the United States.

The letter of intent outlines up to 10 Mega Watts of electrical power dedicated specifically to the needs of Microelectronics Technology Company. The electrical rate for this power averages 2 cents per kilowatt, the lowest rate in the Country. The electrical provider rates reliability of the electrical power at 99.99%.

“With this amount of electrical power available to the Company we can now move forward with our expansion plans of a site designed and constructed with a bitcoin mining operation in mind,” stated Brett Everett, President of the Company. “With the new chip technology coming to the market, this also increases the amount of Hash Rate the Company can run with 10 Mega Watts of electrical power, providing us with some very unique options.”

The timing for finalization for delivery of the contract for the power is June 16, 2015 in accordance with the terms outlined in the Letter of Intent.

https://www.facebook.com/btcpoolparty

Additional photos and videos can be viewed at the company’s Facebook page:

https://www.facebook.com/MELYPK.

Forward-Looking Statements:

This news release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. While these statements are made to convey Company progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. Whereas management believes such representations to be true and accurate based on information and data available to the Company at this time, actual results may differ materially and are subject to risk and uncertainties. Factors that may cause actual results to differ include without limitation: dependence on key personnel and suppliers; MELY’s ability to commercialize its technology; ability to defend intellectual property; material and component costs; competition; economic conditions; consumer demand and product acceptance, and availability of growth capital.

Additional considerations and risk factors are set forth-in reports filed on Form 8-K and 10-K with the SEC and other filings. Readers are cautioned not to place undue reliance upon these forward-looking statements; historical information is not an indicator of future performance. The Company undertakes no obligation to update publicly any forward-looking statements.

CONTACT:

For further Information:

Microelectronics Technology Company
President:
Mr. Brett Everett
888-681-9777 ext. 5
info@melypk.com
www.melypk.com

SOURCE: Microelectronics Technology Company

ReleaseID: 429358

CORAL GABLES, FL / ACCESSWIRE / May 29, 2015 / The Nasdaq Biotechnology Index is up significantly over the last 5 years with a good majority of positive momentum kicking in during the last 18 months. Since levels hovering around 830 this time in 2010, you can quickly begin to see the massive growth that this market has seen especially since the NBI hit over 3,900 this year. The sharpest increase on the index hasn’t been until recently from 2014- present and with the amount of IPO’s and mergers & acquisitions buzz, biotech stocks have captured the interests of many. Oncothyreon, Inc. (ONTY), Amarin Corp. Plc (AMRN), and Accurexa Inc. (ACXA) have begun to become more familiar with today’s biotech investors.

Oncothyreon, Inc. announced this week that Robert Kirkman, M.D., President and Chief Executive Officer, is scheduled to present at the Jefferies 2015 Healthcare Conference in June. Share price of Oncothyreon has increased by as much as 158% since the first of May. The Company has two drug candidates in development, ONT-10, a therapeutic vaccine targeting MUC1, a glycoprotein amplified in most solid epithelial tumor cancers and common non-solid tumors, and ONT-380, an orally active, reversible and small molecule selective inhibitor of human epidermal growth factor receptor 2 (HER2). HER2 is also amplified in many types of cancers, including breast, ovarian and stomach.

Amarin Corp. Plc also announced this week that Amarin’s President and Chief Executive Officer, John F. Thero, is scheduled to present a general company update at the Jefferies 2015 Global Healthcare Conference. Though some are speculating on short interest in Amarin, price movement has suggested the opposite to that over the last 3 days. Since opening the week at $1.90, shares of AMRN have jumped by as much as 47% following Thursday highs of $2.80. Amarin focuses more on cardiovascular health. Currently the company’s first product Vascepa(R) (icosapent ethyl) capsules, is a highly pure EPA omega-3 prescription product.

Seen as newer to the street, ironically, Accurexa Inc has been recently featured on “New To The Street,” a financial broadcast, which airs in New York, LA, Philadelphia, Boston and Miami. George Yu, CEO, Accurexa, Inc. spoke about the Company’s technology for brain cancer and stem cell therapy using its BranchPoint Device. Earlier this year, Accurexa was qualified as a small business by the FDA under its Medical Device User Fee Amendment and allows the company to take advantage of reduced or waived fees for medical device submissions made during fiscal year 2015. Though this is new to the market, interest surrounding its BranchPoint Device has begun to take hold. The device was invented to deliver therapeutics, such as stem cells or gene therapy vectors, through the radial deployment of a flexible catheter to specific brain target areas through a single brain penetration.

The benefits of this device have been seen in certain studies. In fact, according to Accurexa, the current standard of care is the use of straight, rigid needles, that require surgeons to penetrate the brain several times for delivering therapeutics and can actually increase the risk of bleeding, stroke and reflux of therapeutics back out to the brain surface. An animal study* at the University of California, San Francisco demonstrated that the use of a straight needle was associated with reflux of at least 75% of the infusion while no reflux was found with the BranchPoint device.

* Silvestrini MT, Yin D, Coppes VG, Mann P, Martin AJ, Larson PS, Starr PA, Gupta N, Panter SS, Desai TA, Lim DA. Radially branched deployment for more efficient cell transplantation at the scale of the human brain. Stereotact Funct Neurosurg. 2013;91(2):92-103.

ABOUT US:

www.DailyStockReporter.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals www.DailyStockReporter.com is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. You can subscribe to the www.DailyStockReporter.com newsletter and start receiving daily alerts. To subscribe by phone and receive messages directly to a mobile phone, text the phrase “StockAlerts” to 63566.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements.

EGM FIRM INC which owns www.DailyStockReporter.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release.
EGM FIRM INC, which owns www.DailyStockReporter.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice.

EGM FIRM INC which owns www.DailyStockReporter.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

CONTACT:

Company: EGM FIRM INC.
Contact Email: adam@egmfirm.com

SOURCE: BiotechStocks.com

ReleaseID: 429353